# A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

> **NCT05576077** · PHASE1 · TERMINATED · sponsor: **Turnstone Biologics, Corp.** · enrollment: 31 (actual)

## Conditions studied

- Breast Cancer
- Colorectal Cancer
- Uveal Melanoma
- Cutaneous Melanoma
- Non-Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** TBio-4101
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05576077
- **Lead sponsor:** Turnstone Biologics, Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-17
- **Primary completion:** 2025-02-04
- **Final completion:** 2025-02-24
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576077, "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05576077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*